Evaluating GLP-1 receptor agonists versus metformin as first-line therapy for reducing dementia risk in type 2 diabetes
Main finding · Overall dementiaResult — go to the resultAdjusted hazard ratio 0.90 95% CI 0.85–0.95Authors' conclusion
GLP-1 RAs were more effective than metformin in reducing the risk of dementia-especially AD and non-vascular types-highlighting their potential as a preferred first-line treatment in T2DM. Further randomized trials are warranted to validate these findings.
Study context
- Population
- Patients with T2D initiating GLP-1 RA or metformin as first-line monotherapy, global health research network, 2004–2024matched cohort
- Participants
- 87,229 vs 87,229
- Exposure
- GLP-1 RA vs metformin as first-line monotherapy
- GLP-1 RAsn = 87,229
- Metforminn = 87,229reference
- Outcome
- Overall dementia incidence
Methodological detailspropensity score matched, global health research network data, 2004–2024, Cox proportional hazards models, with sensitivity analyses
- Propensity score matched
- Global health research network data, 2004–2024
- Cox proportional hazards models, with sensitivity analyses
Main finding
Overall dementia
Adjusted hazard ratio
0.90
95% CI 0.85–0.95
GLP-1 RAsvs Metformin
aHR 0.90 (95% CI 0.85–0.95)
As reported in the abstract
Observational data: associations, not effects.
Further findings
| Outcome | aHR (95% CI) | |
|---|---|---|
| Alzheimer's disease | 0.88 (0.83–0.94) | |
| Non-vascular dementias | 0.75 (0.70–0.81) | |
| 0.512Adjusted hazard ratio (log scale) |
Vascular dementia
- No significant difference was observed for VaD
Subgroups by age and sex
- Consistent benefit across age and sex, strongest among older adults and females
Original publication
Evaluating GLP-1 receptor agonists versus metformin as first-line therapy for reducing dementia risk in type 2 diabetes. BMJ Open Diabetes Res Care. Published 22 July 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →